# **HINT: Hierarchical Interaction Network for Clinical Trial Outcome Prediction and Integration Strategy for Odin**

## **1\. Executive Summary**

The pharmaceutical industry is currently navigating a period of significant productivity challenges, characterized by rising research and development costs and stagnant success rates for new molecular entities (NMEs). The attrition rate for drug candidates entering clinical development remains dauntingly high, with estimates suggesting that approximately 90% of compounds entering Phase I trials fail to achieve regulatory approval. This systemic inefficiency translates into capitalized costs per approved drug ranging from $2 billion to $3 billion, with failed clinical trials—particularly late-stage Phase III failures—constituting a substantial portion of this expenditure. In this landscape, the ability to accurately predict the outcome of a clinical trial before its commencement represents a transformative capability, enabling strategic portfolio optimization, risk mitigation, and resource reallocation.

This report provides an exhaustive technical analysis of the **Hierarchical Interaction Network for Clinical Trial Outcome Prediction (HINT)**, a state-of-the-art deep learning framework developed by researchers at IQVIA and the Georgia Institute of Technology. Unlike traditional predictive models that rely on static, manually engineered features, HINT employs a dynamic, multi-modal architecture that explicitly models the complex interactions between the drug molecule, the target disease ontology, and the trial protocol's eligibility criteria.

The primary objective of this document is to serve as a comprehensive blueprint for the integration of the HINT model into the **Odin** ecosystem. The analysis confirms that HINT is not merely a theoretical construct but a validated, deployable solution supported by a robust codebase and a large-scale benchmark dataset (TOP) comprising over 17,500 historical trials. The model demonstrates superior predictive performance compared to existing baselines, achieving F1 scores of 0.665 for Phase I, 0.620 for Phase II, and 0.847 for Phase III trials.

The following sections dissect the theoretical underpinnings of the HINT architecture, specifically its use of Graph Neural Networks (GNNs), Message Passing Neural Networks (MPNNs), and BERT-based language modeling. Furthermore, this report details the necessary data engineering pipelines, dependency management, and inference logic required to operationalize HINT within Odin. By following the integration strategy outlined herein, Odin will gain the capability to ingest raw trial parameters and output calibrated probability scores for trial success, thereby empowering decision-makers with data-driven foresight.

## **2\. Strategic Context: The Imperative for In Silico Prediction**

### **2.1 The Clinical Trial Attrition Crisis**

The drug development pipeline is funnel-shaped, beginning with thousands of candidate compounds and narrowing down to a single approved therapy. The most perilous segment of this pipeline is the clinical trial phase, where human testing determines safety and efficacy. Historical data reveals a harsh reality: the probability of success (PoS) for a drug transitioning from Phase I to approval is roughly 10%. This high failure rate is not uniform across phases; Phase II, often termed the "valley of death," exhibits the highest attrition as it is the first true test of efficacy in patients. However, Phase III failures are the most financially devastating, often occurring after hundreds of millions of dollars have been invested.

The causes of trial failure are multifarious. They include lack of clinical efficacy (the drug does not work), unmanageable toxicity (the drug is unsafe), and poor study design (the trial cannot prove the drug works). Traditional risk assessment methods in the pharmaceutical industry have relied on key opinion leader (KOL) consensus and historical success rates averaged by therapeutic area. While useful, these heuristics fail to account for the specific, granular characteristics of a given trial—how a specific chemical structure might interact with a specific patient sub-population defined by unique exclusion criteria.

### **2.2 The Evolution of Predictive Analytics in Pharma**

The application of machine learning to trial outcome prediction has evolved through several distinct generations. First-generation models utilized logistic regression or random forests trained on structured metadata, such as the sponsor's reputation, the number of participating sites, and the therapeutic indication. While these models captured high-level trends, they treated the drug and the disease as categorical labels, ignoring the underlying biological and chemical reality.

Second-generation models began to incorporate more features but often struggled with missing data and the "black box" nature of predictions. They failed to provide interpretability regarding *why* a trial was predicted to fail. Was it the molecule? The protocol? Or the interaction between them?

HINT represents the third generation of predictive modeling: **interaction-centric deep learning**. By leveraging the advancements in Geometric Deep Learning and Natural Language Processing (NLP), HINT does not simply correlate features; it simulates the trial components as a hierarchical graph. This approach aligns with the systemic nature of clinical trials, where success is defined by the harmonious interaction of the agent (drug), the subject (disease population), and the rules of engagement (protocol). Integrating this capability into Odin places the system at the cutting edge of *in silico* clinical development.

## **3\. Theoretical Framework and Model Architecture**

The HINT model architecture is a sophisticated assembly of specialized neural networks, each designed to encode a specific modality of clinical trial data. These encoded representations are then fused into a hierarchical interaction graph to predict the trial outcome. Understanding this architecture is prerequisite to successful implementation in Odin.

### **3.1 Multi-Modal Input Encoding**

Clinical trials are defined by heterogeneous data types: chemical structures (graphs), disease classifications (hierarchies), and protocols (unstructured text). HINT employs dedicated encoders for each.

#### **3.1.1 Drug Molecule Encoding: Message Passing Neural Networks (MPNN)**

The fundamental unit of a pharmaceutical intervention is the drug molecule. Traditional cheminformatics approaches represent molecules using fixed-length bit vectors known as fingerprints (e.g., Morgan fingerprints or MACCS keys). While computationally efficient, fingerprints often lose spatial and topological information crucial for determining biological activity.

HINT adopts a **Message Passing Neural Network (MPNN)** to generate dynamic molecular embeddings. The input to this module is the **SMILES** (Simplified Molecular Input Line Entry System) string of the drug. The MPNN treats the molecule as a graph ![][image1], where atoms are nodes and chemical bonds are edges. During the forward pass, the network executes an iterative message-passing phase where each atom receives latent feature information from its neighbors. This process mimics the distribution of electron density and chemical forces within the molecule.

After ![][image2] iterations of message passing, a readout function aggregates the node features into a single graph-level embedding vector. This vector encapsulates not just the presence of substructures, but the holistic physicochemical properties of the drug, such as solubility, lipophilicity, and ligand-binding potential. This rich representation allows HINT to detect subtle structural flaws that might lead to toxicity or lack of potency.

#### **3.1.2 Disease Ontology Encoding: GRAM and Hierarchical Embedding**

Diseases are rarely isolated entities; they exist within a taxonomical hierarchy. For example, "Non-Small Cell Lung Cancer" (NSCLC) shares biological pathways with "Lung Cancer," which shares features with "Respiratory Neoplasms." A model that treats NSCLC as a unique, independent label fails to leverage the wealth of data available for the broader categories.

To address this, HINT utilizes the **ICD-10 (International Classification of Diseases, 10th Revision)** coding system. The model employs a hierarchical embedding technique, conceptually similar to **GRAM (Graph-based Attention Model)**, to represent diseases. The input is the specific ICD-10 node associated with the trial's indication. The encoder aggregates information from the node's ancestors in the ontology tree.

This hierarchical approach provides two critical benefits for Odin. First, it enables **knowledge transfer**: what the model learns about "Neoplasms" informs its predictions for specific cancer subtypes. Second, it handles **data sparsity**: rare diseases with few historical trials can still be modeled effectively by relying on the embeddings of their more common parent categories. The output is a dense vector representing the disease context, enriched by its taxonomical lineage.

#### **3.1.3 Protocol Encoding: BERT for Eligibility Criteria**

The inclusion and exclusion criteria of a clinical trial define the patient population. These criteria are critical determinants of trial success; overly restrictive criteria can lead to recruitment failure, while overly broad criteria can dilute the efficacy signal or introduce safety risks. These criteria are typically recorded as unstructured free text.

HINT leverages **BERT (Bidirectional Encoder Representations from Transformers)** to encode this textual data. Specifically, the model utilizes a pre-trained BERT variant (such as BioBERT or ClinicalBERT) which has been fine-tuned on large corpora of biomedical literature. The preprocessing pipeline extracts the eligibility criteria text from the trial protocol, tokenizes it, and feeds it into the Transformer architecture.

Unlike simple "Bag-of-Words" models that count keyword frequencies, BERT captures the contextual semantics of the criteria. It distinguishes between "Patient has a history of diabetes" (Inclusion) and "Patient must not have a history of diabetes" (Exclusion). The pooled output of the Transformer (typically the \`\` token embedding) serves as the vector representation of the trial protocol.

### **3.2 The Knowledge Embedding Module**

Raw embeddings of drugs and diseases are necessary but insufficient. To predict success, the model needs to understand specific properties that drive failure, such as toxicity (ADMET) and pharmacokinetic risks. HINT incorporates a **Knowledge Embedding Module** that is pre-trained on external tasks.

The drug encoder, for instance, is often pre-trained to predict **ADMET** (Absorption, Distribution, Metabolism, Excretion, and Toxicity) properties using databases like DrugBank. This pre-training forces the molecular embedding to prioritize features relevant to safety and drug-likeness. When the MPNN is subsequently used in the HINT pipeline, it carries this "prior knowledge" about what makes a molecule safe. This is a crucial differentiator from models that learn strictly from trial outcomes, as the signal for toxicity in trial data is often sparse and noisy.

### **3.3 The Hierarchical Interaction Graph**

The core innovation of HINT is the **Interaction Graph**. Most deep learning models fusion multi-modal data by simply concatenating the feature vectors (![][image3]). This "early fusion" assumes that the relationship between modalities is linear or can be easily disentangled by subsequent dense layers.

HINT, conversely, constructs a dynamic graph where the drug, disease, and protocol are distinct nodes connected by edges representing their interactions.

* **Drug-Disease Edge:** Captures the therapeutic hypothesis (mechanism of action).  
* **Drug-Protocol Edge:** Captures risks related to the drug's properties and the chosen population (e.g., a drug with renal clearance issues interacting with a protocol that allows patients with mild kidney disease).  
* **Disease-Protocol Edge:** Captures the appropriateness of the criteria for the condition (e.g., are the inclusion criteria standard for this disease?).

A Graph Neural Network (GNN) then operates on this interaction graph. An **attention mechanism** dynamically weights the edges for each specific trial. For one trial, the attention might focus heavily on the drug-disease fit; for another, it might highlight a mismatch between the protocol and the disease severity. This dynamic weighting provides a form of interpretability, allowing Odin users to potentially inspect which interaction is driving a negative prediction.

### **3.4 Outcome Prediction and Optimization**

The final stage of the architecture is the prediction head. The state of the interaction graph is pooled into a global trial embedding, which is passed through a Multi-Layer Perceptron (MLP) with a sigmoid activation function. This outputs a scalar probability score ![][image4], representing the likelihood of trial success (approval or transition to the next phase).

The model is trained using binary cross-entropy loss, optimizing the parameters of the encoders and the GNN simultaneously. The training process utilizes the large-scale TOP benchmark dataset to learn the complex, non-linear patterns governing trial outcomes.

## **4\. Data Engineering and the TOP Benchmark**

Data is the fuel for the HINT engine. The robustness of the model depends entirely on the quality and scale of the data it was trained on. For integration into Odin, it is essential to understand the data structures used during training to ensure the inference data pipeline is perfectly aligned.

### **4.1 The TOP Benchmark Dataset**

The authors of HINT curated and released the **Trial Outcome Prediction (TOP)** benchmark dataset. This dataset is sourced primarily from **ClinicalTrials.gov**, enriched with data from **DrugBank** and ICD-10 coding resources.

**Dataset Composition:**

* **Total Trials:** 17,538 clinical trials.  
* **Phase Distribution:**  
  * **Phase I:** \~1,787 trials (High attrition due to toxicity).  
  * **Phase II:** \~6,102 trials (High attrition due to lack of efficacy).  
  * **Phase III:** \~4,576 trials (Complex, large-scale studies).  
* **Outcome Labels:** Binary labels indicating success (1) or failure (0). Success is defined as the trial completing effectively and the drug advancing to the next phase or receiving FDA approval.

### **4.2 Data Processing Pipeline**

The repository contains a benchmark folder with scripts that transform raw XML downloads from ClinicalTrials.gov into the structured format required by HINT.

1. **collect\_raw\_data.py:** This script parses the XML files. It extracts the NCTID, the intervention name (drug), the condition (disease), and the text block under \<eligibility\>. It filters out trials that are not drug-related (e.g., device or behavioral trials) and those with ambiguous status (e.g., "Recruiting", "Unknown status").  
2. **nctid2date.py:** This utility extracts the start and completion dates of trials. This temporal data is crucial for creating realistic train/test splits. HINT uses a **time-ordered split**, training on older trials and testing on newer ones, to simulate the real-world scenario of predicting future events based on historical knowledge. Odin must respect this temporal logic if retraining is performed.  
3. **icdcode\_encode.py:** This script maps the disease strings found in the XML (e.g., "Major Depressive Disorder") to standard ICD-10 codes (e.g., "F32"). It then builds the ancestor hierarchy dictionary (icdcode2ancestor\_dict.pkl), which is used by the disease encoder module.  
4. **molecule\_encode.py:** This script takes the drug names extracted from the XML and queries chemical databases (like DrugBank or PubChem) to retrieve the corresponding SMILES string. It then processes these strings using RDKit to generate the molecular graph structures used by the MPNN.  
5. **protocol\_encode.py:** This script tokenizes the eligibility criteria text using the BERT tokenizer and generates the latent embeddings. These pre-computed embeddings are stored to accelerate training, though for inference in Odin, this will likely be done on-the-fly.

### **4.3 Input Requirements for Odin**

To utilize the pre-trained HINT models, Odin must supply data in a format identical to the processed TOP benchmark. The crucial elements are:

* **Canonical SMILES:** The drug structure must be a valid, RDKit-canonicalized SMILES string.  
* **Valid ICD-10:** The disease must be mapped to a valid leaf-node code in the ICD-10-CM hierarchy.  
* **Cleaned Text:** The protocol text must be stripped of XML tags and standard formatting noise before embedding.

## **5\. Source Code Audit and Repository Analysis**

A detailed audit of the GitHub repository futianfan/clinical-trial-outcome-prediction reveals the codebase structure and key dependencies. This analysis guides the deployment of the code within Odin's infrastructure.

### **5.1 Repository Structure**

The codebase is modular, separating data preprocessing (benchmark), model definition (HINT), and utility functions.

* **benchmark/**: Contains the ETL (Extract, Transform, Load) scripts described in Section 4.2.  
  * data\_split.py: Handles the generation of training, validation, and testing subsets based on trial phases and dates.  
  * param.py: configuration file for data paths.  
* **HINT/**: The core application logic.  
  * **model.py**: This is the most critical file. It defines the HINTModel class, the Interaction graph layer, and the sub-encoders (MoleculeEncoder, DiseaseEncoder, ProtocolEncoder). It also contains the forward() function which defines the data flow during inference.  
  * **learn\_phaseI.py / II / III**: These are the driver scripts. They handle the loading of data, initialization of the model, the training loop (epochs), and the evaluation metrics. For Odin, these scripts will serve as the template for the inference script.  
  * **train.py**: Generic training utilities.  
* **data/**: Storage for the processed .pkl (pickle) files and the raw\_data.csv.  
* **save\_model/**: This directory stores the serialized PyTorch model weights (.pth files) after training. Odin will need to mount this directory or load these weights into memory.

### **5.2 Dependency Management (conda.yml)**

The conda.yml file provides the exact environment specifications. Adhering to these versions is critical to avoid "dependency hell," particularly with libraries like PyTorch and RDKit which can have breaking changes in their APIs.

**Key Dependencies:**

* **Python 3.7**: The codebase is written for this specific version. Upgrading to Python 3.10+ may break the pickle files or older RDKit bindings.  
* **PyTorch (torch)**: The tensor computation engine.  
* **RDKit (rdkit)**: For chemical graph generation.  
* **icd10-cm**: A Python library for validating and navigating ICD-10 codes.  
* **scikit-learn**: Used for calculating F1, Precision-Recall AUC, and ROC-AUC scores.  
* **Transformers**: While not explicitly detailed in every snippet, the use of BERT implies the need for the Hugging Face transformers library or a similar BERT implementation.

### **5.3 Code Logic Flow**

The execution flow for a single prediction involves:

1. **Instantiation:** model \= HINTModel(...) initializes the sub-modules.  
2. **Loading:** model.load\_state\_dict(torch.load('save\_model/model\_phaseIII.pth')) loads the learned weights.  
3. **Input Preparation:** Data loaders batch the SMILES, ICD codes, and protocol embeddings.  
4. **Forward Pass:** output \= model(drug\_input, disease\_input, protocol\_input).  
5. **Sigmoid:** prob \= torch.sigmoid(output).

## **6\. Implementation Strategy for Odin Integration**

This section outlines the specific architectural steps to integrate HINT into Odin. We assume Odin is a scalable data processing environment capable of running Python-based microservices.

### **6.1 Architecture Overview**

The integration should follow a microservices pattern. A "HINT Service" will expose an API to Odin's main orchestration layer. This service will encapsulate the complex environment (Conda, RDKit, PyTorch) and expose a simple endpoint.

**Components:**

1. **Preprocessing Service:** Handles the normalization of user inputs (Drug Name ![][image5] SMILES, Disease Name ![][image5] ICD-10).  
2. **Inference Engine:** Loads the heavy PyTorch models and runs the prediction.  
3. **Result Aggregator:** Formats the output probability and associated metadata.

### **6.2 Step 1: Environment Provisioning**

The first step is to containerize the HINT environment. A Docker container is recommended to ensure reproducibility.

**Dockerfile Specification (Conceptual):**

Dockerfile

FROM pytorch/pytorch:1.7.1\-cuda11.0\-cudnn8-runtime  
\# Install system dependencies  
RUN apt-get update && apt-get install \-y libxrender1 libxext6  
\# Install Conda environment  
COPY conda.yml.  
RUN conda env create \-f conda.yml  
\# Activate environment  
SHELL \["conda", "run", "-n", "predict\_drug\_clinical\_trial", "/bin/bash", "-c"\]  
\# Install PubChemPy for drug resolution  
RUN pip install pubchempy sentence-transformers  
COPY. /app  
WORKDIR /app

This container ensures that Odin can spin up the HINT model on any node without manual dependency installation.

### **6.3 Step 2: The Preprocessing Pipeline (odin\_preprocess.py)**

Odin users will likely input high-level terms. The system must translate these into the model's language.

**Drug Name Resolution:**

Users will enter "Keytruda" or "Pembrolizumab." The system must query PubChem to get the isomeric SMILES.

Python

import pubchempy as pcp  
from rdkit import Chem

def get\_canonical\_smiles(drug\_name):  
    try:  
        \# Query PubChem  
        compounds \= pcp.get\_compounds(drug\_name, 'name')  
        if not compounds:  
            return None  
        \# Get SMILES  
        smiles \= compounds.isomeric\_smiles  
        \# Canonicalize with RDKit  
        mol \= Chem.MolFromSmiles(smiles)  
        if mol:  
            return Chem.MolToSmiles(mol)  
        return None  
    except Exception as e:  
        \# Log error in Odin  
        return None

**Disease Mapping:**

Users will enter "Breast Cancer." This must be mapped to C50. A lookup table or fuzzy string matching against the icd10-cm library descriptions is required.

Python

import simple\_icd\_10\_cm as cm

def validate\_icd(code):  
    if cm.is\_valid\_item(code):  
        return code  
    \# Implement fallback logic or fuzzy search here  
    return None

**Protocol Embedding:**

The protocol text is often long. The BERT model has a token limit (usually 512 tokens). The preprocessing script must truncate or summarize the text intelligently. The HINT paper suggests using the \`\` token embedding of the raw text.

Python

from sentence\_transformers import SentenceTransformer  
model \= SentenceTransformer('pritamdeka/BioBERT-mnli-snli-scinli-scitail-mednli-stsb')  
def embed\_protocol(text):  
    return model.encode(text)

### **6.4 Step 3: The Inference Wrapper (odin\_inference.py)**

This script acts as the bridge between the preprocessed data and the PyTorch model. It must handle the forward() pass correctly.

Python

import torch  
from HINT.model import HINTModel

class OdinHINTWrapper:  
    def \_\_init\_\_(self, phase, model\_path, device='cpu'):  
        self.device \= device  
        \# Initialize model with hyperparameters matching training  
        \# Note: These params must match the config in param.py from training  
        self.model \= HINTModel(num\_features\_mol=128,   
                               num\_features\_gram=128,   
                               num\_features\_protocol=768,   
                               output\_dim=128)  
          
        \# Load weights  
        self.model.load\_state\_dict(torch.load(model\_path, map\_location=device))  
        self.model.to(device)  
        self.model.eval()

    def predict(self, smiles\_graph, icd\_ancestors, protocol\_embedding):  
        \# Convert inputs to tensors  
        \# Pass through model  
        with torch.no\_grad():  
            output \= self.model(smiles\_graph, icd\_ancestors, protocol\_embedding)  
            probability \= torch.sigmoid(output).item()  
        return probability

*Note: The smiles\_graph input requires the specialized collate function from molecule\_encode.py to batch the geometric data structures correctly.*

### **6.5 Step 4: Output Calibration and Display**

The raw probability (e.g., 0.65) requires context. Odin should display:

1. **The Probability Score:** "65% Chance of Success."  
2. **Confidence Interval:** (If available via uncertainty quantification methods, though standard HINT provides a point estimate).  
3. **Baseline Context:** "Average Phase II Success Rate is \~30%. This trial is significantly above average."  
4. **Model Reliability:** Display the F1 score for the specific phase (e.g., "Model Phase II Accuracy: 62%").

## **7\. Validation and Performance Analysis**

To rely on HINT for critical decision-making within Odin, one must understand its performance profile and limitations. The authors conducted extensive validation using the TOP benchmark.

### **7.1 Quantitative Performance**

The model was evaluated using standard classification metrics: **F1 Score** (harmonic mean of precision and recall), **PR-AUC** (Area Under the Precision-Recall Curve), and **ROC-AUC**.

| Metric | Phase I | Phase II | Phase III |
| :---- | :---- | :---- | :---- |
| **HINT F1 Score** | **0.665** | **0.620** | **0.847** |
| Baseline (DeepEnroll) | 0.612 | 0.585 | 0.792 |
| Baseline (Random Forest) | 0.580 | 0.540 | 0.710 |

**Analysis:**

* **Phase III Strength:** HINT excels at predicting Phase III outcomes (F1 0.847). This is intuitive; by Phase III, the drug has passed safety (Phase I) and initial efficacy (Phase II) tests. The remaining variables are often related to large-scale population interactions and protocol design—factors that HINT's interaction graph is specifically designed to capture.  
* **Phase II Challenge:** The lower performance in Phase II (0.620) reflects the inherent high risk and biological uncertainty of this phase. Phase II is often the first time the drug is tested for efficacy in humans, meaning there are "unknown unknowns" that no historical data model can fully anticipate.  
* **Superiority over Baselines:** HINT consistently outperforms feature-based models (Random Forest) and other deep learning baselines (DeepEnroll), validating the efficacy of the hierarchical interaction graph approach.

### **7.2 Ablation Studies**

The research includes ablation studies that selectively disable parts of the model to test their importance.

* **Without Knowledge Embedding:** Performance drops significantly. This confirms that pre-training on ADMET properties (toxicity) is crucial for success prediction.  
* **Without Interaction Graph:** Performance drops. This confirms that simply concatenating drug and disease features is inferior to explicitly modeling their interaction edges.

### **7.3 Case Studies**

The paper highlights specific real-world validations.

* **Oncology:** HINT successfully predicted the failure of certain high-profile cancer trials where the drug mechanism (encoded by MPNN) did not align well with the specific sub-indication (encoded by ICD-10 hierarchy).  
* **COVID-19:** In retrospective analysis, the model showed promise in identifying repurposed drugs with higher probabilities of success for viral respiratory indications, leveraging the shared ontology between COVID-19 and other viral pneumonias.

## **8\. Operational Maintenance and Troubleshooting**

Deploying a research model into production (Odin) requires awareness of potential operational pitfalls.

### **8.1 "Out of Distribution" Data**

HINT was trained on trials up to \~2021. If Odin users query extremely novel modalities (e.g., a complex CRISPR gene-editing therapy or a radioligand), the MPNN encoder may struggle because these structures are underrepresented in the training data.

* **Mitigation:** Implement a "Confidence Flag." If the input SMILES similarity to the training set is low (measurable via Tanimoto similarity), Odin should warn the user: *"Low Confidence: Novel molecular structure detected."*

### **8.2 Input Formatting Errors**

A common source of failure is the SMILES string format.

* **Issue:** C(=O)O and OC=O are the same molecule but different strings.  
* **Fix:** The preprocessing pipeline *must* enforce RDKit canonicalization. If RDKit cannot parse the SMILES, the request should fail gracefully with a clear error message to the user, rather than passing garbage to the MPNN.

### **8.3 PyTorch Forward Function Confusion**

As noted in the research snippets, there is often confusion regarding the forward() method in PyTorch.

* **Clarification:** The forward() method is called implicitly when the model object is called as a function (i.e., model(inputs)). Odin developers should *not* call model.forward(inputs) directly, although it works, as it bypasses PyTorch's internal hook registration system which is useful for debugging and logging.

### **8.4 Retraining Schedule**

Clinical knowledge advances daily. To maintain the F1 scores cited above, the HINT model in Odin must be retrained periodically.

* **Strategy:** Automated scripts should scrape ClinicalTrials.gov every 6 months to append new completed trials to the TOP benchmark CSV. The learn\_phaseX.py scripts can then be triggered to fine-tune the weights on this expanded dataset.

## **9\. Future Roadmap and Advanced Integration**

Looking beyond the initial integration, several advanced capabilities can be explored to enhance Odin's predictive power.

### **9.1 Uncertainty Quantification**

Recent work (mentioned in snippets referencing "Uncertainty Quantification") suggests augmenting HINT with methods to output a probability distribution rather than a point estimate. This would allow Odin to say "60% success chance ![][image6] 15%," providing a clearer picture of risk for Phase II trials.

### **9.2 LLM-Augmented Preprocessing**

Large Language Models (like GPT-4 or specialized clinical LLMs) can replace the static BERT embeddings for protocol encoding. An LLM could generate a more nuanced summary of the eligibility criteria, potentially extracting "hidden" risks in the text that standard BERT embeddings miss. This concept aligns with the "TrialGPT" approach mentioned in the research snippets.

### **9.3 Integration with Trial Enrollment Prediction**

Success is not just about biology; it is also about operations. If a trial cannot recruit patients, it fails. Parallel models like "TrialEnroll" (predicting recruitment success) could be integrated alongside HINT. Odin could then offer a composite score: *Biological Success Probability* (HINT) ![][image7] *Operational Success Probability* (TrialEnroll).

## **10\. Conclusion**

The integration of HINT into Odin represents a significant leap forward in data-driven clinical strategy. By moving beyond simple historical averages and embracing the complexity of interaction networks, Odin can provide pharmaceutical stakeholders with a sophisticated lens through which to view portfolio risk.

The HINT model is theoretically sound, architecturally robust, and empirically validated. The challenges for integration are primarily engineering-focused: establishing reliable data pipelines for chemical and clinical data normalization. By adhering to the architectural blueprints and operational safeguards detailed in this report, the Odin team can successfully deploy this capability, transforming raw clinical data into actionable strategic foresight.

### ---

**Key Resources Table**

| Resource | Description | URL / Location |
| :---- | :---- | :---- |
| **Source Code** | Official GitHub Repository | https://github.com/futianfan/clinical-trial-outcome-prediction |
| **Research Paper** | Original Publication in *Patterns* | https://www.iqvia.com/-/media/iqvia/pdfs/library/white-papers/hint-hierarchical-interaction-network-for-clinical-trial-outcome-prediction-insight-brief.pdf |
| **Benchmark Data** | TOP Dataset (17k+ trials) | benchmark/ folder in repo |
| **Model Weights** | Pre-trained .pth files | save\_model/ folder in repo |
| **Dependency File** | Conda Environment Config | conda.yml in repo |

**Citation:**

1

#### **Works cited**

1. HINT: Hierarchical Interaction Network for Clinical Trial Outcome Prediction \- IQVIA, accessed January 26, 2026, [https://www.iqvia.com/-/media/iqvia/pdfs/library/white-papers/hint-hierarchical-interaction-network-for-clinical-trial-outcome-prediction-insight-brief.pdf](https://www.iqvia.com/-/media/iqvia/pdfs/library/white-papers/hint-hierarchical-interaction-network-for-clinical-trial-outcome-prediction-insight-brief.pdf)  
2. HINT: Hierarchical interaction network for clinical-trial-outcome predictions \- PMC \- NIH, accessed January 26, 2026, [https://pmc.ncbi.nlm.nih.gov/articles/PMC9024011/](https://pmc.ncbi.nlm.nih.gov/articles/PMC9024011/)  
3. (PDF) HINT: Hierarchical interaction network for clinical-trial-outcome predictions, accessed January 26, 2026, [https://www.researchgate.net/publication/360202082\_HINT\_Hierarchical\_interaction\_network\_for\_clinical-trial-outcome\_predictions](https://www.researchgate.net/publication/360202082_HINT_Hierarchical_interaction_network_for_clinical-trial-outcome_predictions)  
4. benchmark dataset and Deep learning method (Hierarchical Interaction Network, HINT) for clinical trial approval probability prediction, published in Cell Patterns 2022\. \- GitHub, accessed January 26, 2026, [https://github.com/futianfan/clinical-trial-outcome-prediction](https://github.com/futianfan/clinical-trial-outcome-prediction)  
5. \[2102.04252\] HINT: Hierarchical Interaction Network for Trial Outcome Prediction Leveraging Web Data \- arXiv, accessed January 26, 2026, [https://arxiv.org/abs/2102.04252](https://arxiv.org/abs/2102.04252)  
6. tutorial\_HINT.ipynb \- futianfan/clinical-trial-outcome-prediction \- GitHub, accessed January 26, 2026, [https://github.com/futianfan/clinical-trial-outcome-prediction/blob/main/tutorial\_HINT.ipynb](https://github.com/futianfan/clinical-trial-outcome-prediction/blob/main/tutorial_HINT.ipynb)  
7. clinical-trial-prediction/clinical\_trial\_embedding\_tutorial.ipynb at main \- GitHub, accessed January 26, 2026, [https://github.com/lenlan/clinical-trial-prediction/blob/main/clinical\_trial\_embedding\_tutorial.ipynb](https://github.com/lenlan/clinical-trial-prediction/blob/main/clinical_trial_embedding_tutorial.ipynb)  
8. clinical-trial-outcome-prediction/HINT/README.md at main \- GitHub, accessed January 26, 2026, [https://github.com/futianfan/clinical-trial-outcome-prediction/blob/main/HINT/README.md](https://github.com/futianfan/clinical-trial-outcome-prediction/blob/main/HINT/README.md)  
9. Clinical Trial Information Extraction with BERT \- arXiv, accessed January 26, 2026, [https://arxiv.org/pdf/2110.10027](https://arxiv.org/pdf/2110.10027)  
10. Simplified Molecular Input Line Entry System \- Wikipedia, accessed January 26, 2026, [https://en.wikipedia.org/wiki/Simplified\_Molecular\_Input\_Line\_Entry\_System](https://en.wikipedia.org/wiki/Simplified_Molecular_Input_Line_Entry_System)  
11. (PDF) HINT: Hierarchical Interaction Network for Trial Outcome Prediction Leveraging Web Data \- ResearchGate, accessed January 26, 2026, [https://www.researchgate.net/publication/349124972\_HINT\_Hierarchical\_Interaction\_Network\_for\_Trial\_Outcome\_Prediction\_Leveraging\_Web\_Data](https://www.researchgate.net/publication/349124972_HINT_Hierarchical_Interaction_Network_for_Trial_Outcome_Prediction_Leveraging_Web_Data)  
12. clinical-trial-outcome-prediction/benchmark/README.md at main \- GitHub, accessed January 26, 2026, [https://github.com/futianfan/clinical-trial-outcome-prediction/blob/main/benchmark/README.md](https://github.com/futianfan/clinical-trial-outcome-prediction/blob/main/benchmark/README.md)  
13. Understanding the Forward Function Output in PyTorch \- GeeksforGeeks, accessed January 26, 2026, [https://www.geeksforgeeks.org/deep-learning/understanding-the-forward-function-output-in-pytorch/](https://www.geeksforgeeks.org/deep-learning/understanding-the-forward-function-output-in-pytorch/)  
14. PubChemPy Drug names to Smiles \- Kaggle, accessed January 26, 2026, [https://www.kaggle.com/code/mpwolke/pubchempy-drug-names-to-smiles](https://www.kaggle.com/code/mpwolke/pubchempy-drug-names-to-smiles)  
15. How to convert chemical formula to SMILES? \- Matter Modeling Stack Exchange, accessed January 26, 2026, [https://mattermodeling.stackexchange.com/questions/14318/how-to-convert-chemical-formula-to-smiles](https://mattermodeling.stackexchange.com/questions/14318/how-to-convert-chemical-formula-to-smiles)  
16. Converting molecule name to SMILES? \- python \- Stack Overflow, accessed January 26, 2026, [https://stackoverflow.com/questions/54930121/converting-molecule-name-to-smiles](https://stackoverflow.com/questions/54930121/converting-molecule-name-to-smiles)  
17. icd-mappings \- PyPI, accessed January 26, 2026, [https://pypi.org/project/icd-mappings/](https://pypi.org/project/icd-mappings/)  
18. StefanoTrv/simple\_icd\_10\_CM: A simple python library for ICD-10-CM codes \- GitHub, accessed January 26, 2026, [https://github.com/StefanoTrv/simple\_icd\_10\_CM](https://github.com/StefanoTrv/simple_icd_10_CM)  
19. Exploring LLMs for ICD Coding — Part 1 | by Anand Subramanian | TDS Archive | Medium, accessed January 26, 2026, [https://medium.com/data-science/exploring-llms-for-icd-coding-part-1-959e48b58b9e](https://medium.com/data-science/exploring-llms-for-icd-coding-part-1-959e48b58b9e)

[image1]: <data:image/png;base64,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>

[image2]: <data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAAsAAAAXCAYAAADduLXGAAAA4UlEQVR4XuXSoYpCQRTG8SMquKigGA0iirDNBzBqsrnR4AtYtBjFKJpsxu2iGOyC0bppk0Fs+wIK6v/cOwMy94p1wQ9+cOfMwJk5XJF/mQhyyLgbbsY444a+sxeaFi6ouRthmeGAvFMPJI0dNkg4e4F84g8Ds9bHVtDAhz1k08YVdcQxwgRrCXmwvW8JQ1TFPxSYThZ7/GAu/pU0eo0ekmbt5XFkZfxiJU8e6o7sW/xO2rGJjqlLClssEDM1PaxrncIURVOXAk7o2gL5whFLU9cxetEPbRe1BRPt+PKHet/cAcfeIy832IBiAAAAAElFTkSuQmCC>

[image3]: <data:image/png;base64,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>

[image4]: <data:image/png;base64,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>

[image5]: <data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAABMAAAAXCAYAAADpwXTaAAAAiElEQVR4XmNgGAWjgGqAA4jTgJgHXYIcwAjErUBsjC5BLgAZ1AvELOgS5ACQ6wqAOA7KRgECQCxJIpYD4vlAPBmI+RiggBuIq4F4Fhl4BxB/BeJmIGZnoACYAPFqIJZBlyAVCAPxYiCWR5cgB2QBcQS6IDkAlGinArE0ugQ5AJQUeKH0KBhMAABVixNKp22j3QAAAABJRU5ErkJggg==>

[image6]: <data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAA8AAAAXCAYAAADUUxW8AAAAUElEQVR4XmNgGAXIQACIQ4GYEV2CGCAJxAuBmAddghgwnDVzA/EKIH6Ehp8B8S8gfoJFrgmsEw8gymZcYDhrFgLiHQyYIYovtGvBOkcBHQEAx7keR5q32rYAAAAASUVORK5CYII=>

[image7]: <data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAA8AAAAXCAYAAADUUxW8AAAAjUlEQVR4XmNgGAVDEHADsTi6IBJgBGIpIGZGlwABUSBeBcQm6BIMEI0JQDwZiFlRpRBABoh3ALEZkhhRGmEA2QCSNMIAzIApDCRqBAGQjUVA/BqIrdDk8AKQxhwGiI1yQLyeATUMcAJkjTCnSjAQYQBIYxYQT2DA9CNBA7SAuIkBUyMMCAFxF5QeBXQHAMRmESwieeNfAAAAAElFTkSuQmCC>